Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 197

1.

Virulence of pertactin-negative Bordetella pertussis isolates from infants, France.

Bodilis H, Guiso N.

Emerg Infect Dis. 2013 Mar;19(3):471-4. doi: 10.3201/1903.121475.

2.

Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia.

Lam C, Octavia S, Ricafort L, Sintchenko V, Gilbert GL, Wood N, McIntyre P, Marshall H, Guiso N, Keil AD, Lawrence A, Robson J, Hogg G, Lan R.

Emerg Infect Dis. 2014 Apr;20(4):626-33. doi: 10.3201/eid2004.131478.

3.

Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage.

Martin SW, Pawloski L, Williams M, Weening K, DeBolt C, Qin X, Reynolds L, Kenyon C, Giambrone G, Kudish K, Miller L, Selvage D, Lee A, Skoff TH, Kamiya H, Cassiday PK, Tondella ML, Clark TA.

Clin Infect Dis. 2015 Jan 15;60(2):223-7. doi: 10.1093/cid/ciu788. Epub 2014 Oct 9.

PMID:
25301209
4.

Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin.

Hegerle N, Paris AS, Brun D, Dore G, Njamkepo E, Guillot S, Guiso N.

Clin Microbiol Infect. 2012 Sep;18(9):E340-6. doi: 10.1111/j.1469-0691.2012.03925.x. Epub 2012 Jun 21.

5.

Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines.

Hegerle N, Guiso N.

Expert Rev Vaccines. 2014 Sep;13(9):1135-46. doi: 10.1586/14760584.2014.932254. Epub 2014 Jun 23. Review.

PMID:
24953157
6.

Pertactin-negative variants of Bordetella pertussis in New York State: a retrospective analysis, 2004-2013.

Quinlan T, Musser KA, Currenti SA, Zansky SM, Halse TA.

Mol Cell Probes. 2014 Aug;28(4):138-40. doi: 10.1016/j.mcp.2013.12.003. Epub 2013 Dec 21.

PMID:
24365130
8.

Pertactin-negative Bordetella pertussis strains in Canada: characterization of a dozen isolates based on a survey of 224 samples collected in different parts of the country over the last 20 years.

Tsang RS, Shuel M, Jamieson FB, Drews S, Hoang L, Horsman G, Lefebvre B, Desai S, St-Laurent M.

Int J Infect Dis. 2014 Nov;28:65-9. doi: 10.1016/j.ijid.2014.08.002. Epub 2014 Sep 22.

9.

Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model.

Safarchi A, Octavia S, Luu LD, Tay CY, Sintchenko V, Wood N, Marshall H, McIntyre P, Lan R.

Vaccine. 2015 Nov 17;33(46):6277-81. doi: 10.1016/j.vaccine.2015.09.064. Epub 2015 Oct 2.

PMID:
26432908
10.

A natural pertactin deficient strain of Bordetella pertussis shows improved entry in human monocyte-derived dendritic cells.

Stefanelli P, Fazio C, Fedele G, Spensieri F, Ausiello CM, Mastrantonio P.

New Microbiol. 2009 Apr;32(2):159-66.

11.

Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012.

Zeddeman A, van Gent M, Heuvelman CJ, van der Heide HG, Bart MJ, Advani A, Hallander HO, Wirsing von Konig CH, Riffelman M, Storsaeter J, Vestrheim DF, Dalby T, Krogfelt KA, Fry NK, Barkoff AM, Mertsola J, He Q, Mooi F.

Euro Surveill. 2014 Aug 21;19(33). pii: 20881.

12.

Bordetella pertussis Strain Lacking Pertactin and Pertussis Toxin.

Williams MM, Sen K, Weigand MR, Skoff TH, Cunningham VA, Halse TA, Tondella ML; CDC Pertussis Working Group.

Emerg Infect Dis. 2016 Feb;22(2):319-322. doi: 10.3201/eid2202.151332.

13.

Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States.

Pawloski LC, Queenan AM, Cassiday PK, Lynch AS, Harrison MJ, Shang W, Williams MM, Bowden KE, Burgos-Rivera B, Qin X, Messonnier N, Tondella ML.

Clin Vaccine Immunol. 2014 Feb;21(2):119-25. doi: 10.1128/CVI.00717-13. Epub 2013 Nov 20.

14.

Clinical Manifestations and Molecular Characterization of Pertactin-Deficient and Pertactin-Producing Bordetella pertussis in Children, Philadelphia 2007-2014.

Vodzak J, Queenan AM, Souder E, Evangelista AT, Long SS.

Clin Infect Dis. 2017 Jan 1;64(1):60-66. Epub 2016 Sep 13.

PMID:
27624959
15.

First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin.

Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, Guiso N.

Vaccine. 2009 Oct 9;27(43):6034-41. doi: 10.1016/j.vaccine.2009.07.074. Epub 2009 Aug 8.

PMID:
19666155
16.

Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.

Ausiello CM, Urbani F, La Sala A, Lande R, Piscitelli A, Cassone A.

Dev Biol Stand. 1997;89:315-20.

PMID:
9272365
17.

Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine.

Hegerle N, Dore G, Guiso N.

Vaccine. 2014 Nov 20;32(49):6597-600. doi: 10.1016/j.vaccine.2014.09.068. Epub 2014 Oct 11.

PMID:
25312274
18.

Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs.

Hallander HO, Advani A, Donnelly D, Gustafsson L, Carlsson RM.

J Clin Microbiol. 2005 Jun;43(6):2856-65.

19.
20.

The importance of Bordetella pertussis strains which do not produce virulence factors in the epidemiology of pertussis.

Polak M, LutyƄska A.

Postepy Hig Med Dosw (Online). 2017 May 9;71(0):367-379. Review.

Supplemental Content

Support Center